Skip to main content
SpringerLink
Log in

Introduction to Drug Interactions

  • Chapter
Book cover Drug Interactions in Infectious Diseases

Part of the book series: Infectious Disease ((ID))

Abstract

Human immunodeficiency virus (HIV), more than any other disease, is responsible for the renewed interest in drug interactions by physicians, pharmacists, nurses, scientists, and regulatory agencies. The importance of managing drug interactions in infectious diseases moved to the forefront as more drugs spanning the different classes of infectious disease agents became available to treat HIV and prevent or treat opportunistic infections and HIV-related malignancies. This has led to recognition of the potential for and impact of drug interactions in other infectious diseases and with a variety of anti-infective drug classes. Recent reviews (1–4), including those in this volume, and the development of computerized drug interaction databases (5) further attest to the revived interest and importance of drug interactions in the different therapeutic areas of infectious diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984–996.

    Article  PubMed  CAS  Google Scholar 

  2. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Safety 1998;18:83–97.

    Article  PubMed  CAS  Google Scholar 

  3. Von Rosenstiel N-A, Adam D. Macrolide antibiotics: drug interactions of clinical significance. Drug Safety 1995;13:105–122.

    Google Scholar 

  4. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Safety 1999;20:147–169.

    Article  PubMed  CAS  Google Scholar 

  5. Foisy MM, Tseng A. Development of an interactive computer-assisted program to manage medication therapy in HIV-infected patients. Drug Inf J 1998;32:649–656.

    Google Scholar 

  6. Therapeutic Products Programme Guidance Document. Drug-drug interactions: studies in vitro and in vivo (September 21, 2000). Therapeutics Products Directorate, Health Canada.

    Google Scholar 

  7. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry in vivo drug metabolism/drug interaction studies—study design, data analysis, and recommendations for dosing and labeling (November 1999). US Department of Health and Human Services, Food and Drug Administration.

    Google Scholar 

  8. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry drug metabolism/drug interaction studies in the development process: studies in vitro (April 1997). US Department of Health and Human Services, Food and Drug Administration.

    Google Scholar 

  9. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the investigation of drug interactions (December 1997). The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit.

    Google Scholar 

  10. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533–543.

    PubMed  CAS  Google Scholar 

  11. Gauthier I, Malone M. Drug-food interactions in hospitalized patients. Drug Safety 1998;18:383–393.

    Article  PubMed  CAS  Google Scholar 

  12. Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drug Safety 1998;18:251–272.

    Article  PubMed  CAS  Google Scholar 

  13. D’Arcy PF. Adverse reactions and interactions with herbal medicines. Adverse Drug React Toxicol Rev 1991;10:189–208.

    PubMed  CAS  Google Scholar 

  14. D’Arcy PF. Adverse reactions and interactions. Part 2. Adverse Drug React Toxicol Rev 1993;12:147–162.

    PubMed  CAS  Google Scholar 

  15. Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber, G. Cations in didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993;53:292–297.

    Article  PubMed  CAS  Google Scholar 

  16. Schein JR. Cigarette smoking and clinically significant drug interactions. Ann Pharmacother 1995;29:1139–1148.

    PubMed  CAS  Google Scholar 

  17. Hansten P. Drug interactions. In: Applied Therapeutics: The Clinical Use of Drugs. Vancouver, WA: Applied Therapeutics, 1995, pp. 2–10.

    Google Scholar 

  18. Gibaldi M. Drug interactions: part II. Ann Pharmacother 1992;26:829–834.

    PubMed  CAS  Google Scholar 

  19. Tozer TN, Bois FY, Hauck WW, Chen M-L, Williams RL. Absorption rate vs exposure: which is more useful for bioequivalence testing? Pharm Res 1996;13:453–456.

    Article  PubMed  CAS  Google Scholar 

  20. Rolan PE. Plasma protein binding displacement interactions—why are they still regarded as clinically important? Br J Clin Pharmacol 1994;37:125–128.

    PubMed  CAS  Google Scholar 

  21. MacKichan JJ. Protein binding drug displacement interactions fact or fiction? Clin Pharmacokinet 1989;16:65–73.

    PubMed  CAS  Google Scholar 

  22. Benet LZ, Hoener B-A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115–121.

    Article  PubMed  CAS  Google Scholar 

  23. Halifax KL, Lindup WE, Barry MG, Wiltshire HR, Back DJ. Binding of the HIV protease inhibitor saquinavir to human plasma proteins. Br J Clin Pharmacol 1998;46:291P.

    Google Scholar 

  24. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84–112.

    PubMed  CAS  Google Scholar 

  25. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331–385.

    PubMed  CAS  Google Scholar 

  26. Murillo J, Standiford HC, Holley HP, Tatem BA, Caplan ES. Prophylaxis against enterococcal endocarditis: comparison of the aminoglycoside component of parenteral antimicrobial regimens. Antimicrob Agents Chemother 1980;18:448–453.

    PubMed  CAS  Google Scholar 

  27. Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. DICP, Ann Pharmacother 1990;24:982–988.

    CAS  Google Scholar 

  28. Gosney M, Tallis R. Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital. Lancet 1984;1:564–567.

    Article  Google Scholar 

  29. Shinn AF, Shrewsbury RP, Anderson KW. Development of a computerized drug interaction database (MEDICOM) for use in a patient specific environment. Drug Inf J 1983;17:205–210.

    PubMed  CAS  Google Scholar 

  30. Jinks MJ, Hansten PD, Hirschman JL. Drug interaction exposures in an ambulatory Medicaid population. Am J Hosp Pharm 1979;36:923–927.

    PubMed  CAS  Google Scholar 

  31. Mitchell GW, Stanaszek WF, Nichols NB. Documenting drug-drug Interactions in ambulatory patients. Am J Hosp Pharm 1979;36:653–657.

    PubMed  CAS  Google Scholar 

  32. Cooper JW, Wellins I, Fish KH, Loomis ME. Frequency of potential drug-drug interactions. J Am Pharm Assoc 1975;15:24–31.

    PubMed  Google Scholar 

  33. Durrence CW III, DiPiro JT, May JR, Nesbit RR, Sisley JF, Cooper JW. Potential drug interactions in surgical patients. Am J Hosp Pharm 1985;42:1553–1556.

    PubMed  Google Scholar 

  34. Puckett WH, Visconti JA. An epidemiologic study of the clinical significance of drug-drug interactions in a private community hospital. Am J Hosp Pharm 1971;28:247–253.

    PubMed  Google Scholar 

  35. Foisy MM, Gough K, Quan CM, Harris K, Ibanez D, Phillips A. Hospitalizations due to adverse drug reactions and interactions pre-and post-HAART [abstract B215]. Can J Infect Dis 1999;10(suppl B):24B.

    Google Scholar 

  36. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Safety 1993;9:51–59.

    PubMed  CAS  Google Scholar 

  37. Honig PK, Wortham DC, Amani K, Conner D, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513–1518.

    Article  PubMed  CAS  Google Scholar 

  38. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998;352:1751–1752.

    Article  PubMed  CAS  Google Scholar 

  39. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995;333:664–665.

    Article  PubMed  CAS  Google Scholar 

  40. Pollak PT, Sketris IS, MacKenzie SL, Hewlett TJ. Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann Pharmacother 1995;29:486–488.

    PubMed  CAS  Google Scholar 

  41. Kwan TC, Wahba WW, Wildeman RA. Drug interactions: a retrospective study of its epidemiology, clinical significance and influence upon hospitalization. Can J Hosp Pharm 1979;32:12–16.

    PubMed  CAS  Google Scholar 

  42. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacother 1998;18:1112–1120.

    CAS  Google Scholar 

  43. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996;30:951–954.

    PubMed  CAS  Google Scholar 

  44. Nightingale CH, Quintiliani R. Cost of oral antibiotic therapy. Pharmacother 1997;17:302–307.

    CAS  Google Scholar 

  45. Roberts JS, Watrous ML, Schulz RM, Mauch RP, Nightengale BS. Quantifying the clinical significance of drug-drug interactions: scaling pharmacists’ perceptions of a common interaction classification scheme. Ann Pharmacother 1996;30:926–934.

    PubMed  CAS  Google Scholar 

  46. Steinijans VW, Hartmanns M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991;29:323–328.

    PubMed  CAS  Google Scholar 

  47. Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700–705.

    Article  PubMed  CAS  Google Scholar 

  48. Rybak MJ Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679–687.

    Article  PubMed  CAS  Google Scholar 

  49. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231–238.

    Article  PubMed  CAS  Google Scholar 

  50. Tatro DS, ed. Drug interaction facts. Facts and comparisons. St. Louis, MO: Wolters Kluwer, 1998.

    Google Scholar 

  51. Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. Ann Pharmacother 1998;32:785–793.

    Article  PubMed  CAS  Google Scholar 

  52. Hansten PD, Horn JR, eds. Hansten and Horn’s Drug Interactions Analysis and Management. Vancouver, WA: Applied Therapeutics, 1999.

    Google Scholar 

  53. Von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113–122.

    Article  Google Scholar 

  54. Touw DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P450 enzymes. Drug Metab Drug Interact 1997;14:55–82.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biopharmaceutics, Watson Laboratories, Inc., Corona, CA

    Keith Gallicano PhD (Associate Director)

  2. New York State Department of Health, Ordway Research Institute, Albany, NY

    George Drusano MD (Co-Director)

Authors
  1. Keith Gallicano PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Drusano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Discovery Medicine-Antivirals, GlaxoSmithKline, Research Triangle Park, NC

    Stephen C. Piscitelli PharmD (Director) (Director)

  2. College of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, IL

    Keith A. Rodvold PharmD (Professor of Pharmacy Practice and Associate Professor of Medicine in Pharmacy) (Professor of Pharmacy Practice and Associate Professor of Medicine in Pharmacy)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Gallicano, K., Drusano, G. (2005). Introduction to Drug Interactions. In: Piscitelli, S.C., Rodvold, K.A. (eds) Drug Interactions in Infectious Diseases. Infectious Disease. Humana Press. https://doi.org/10.1385/1-59259-924-9:001

Download citation

  • DOI: https://doi.org/10.1385/1-59259-924-9:001

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-455-5

  • Online ISBN: 978-1-59259-924-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation